Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05066672 · ClinicalTrials.gov registry record · Phase 2

Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression

A Phase 2 study, sponsored by Navitor Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
250
Enrollment target

NCT05066672 is a Phase 2 study that has completed, run by Navitor Pharmaceuticals. The registered enrollment target is 250 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05066672, a Phase 2 study, has completed, sponsored by Navitor Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
250 participants
Enrollment target

Study Summary

This study will evaluate the efficacy and safety of NV-5138 in adults with TRD

Interventions

  • DRUG NV-5138
  • DRUG matched placebo

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2022-01-18
Est. Completion 2025-01-21
Phase Phase 2

Sponsor

Navitor Pharmaceuticals

3 total trials

What the Registry Record Tells You About NCT05066672

The ClinicalTrials.gov registry entry for NCT05066672 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Navitor Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which NV-5138 is the first listed.

NCT05066672 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05066672 about?

NCT05066672 is a clinical study titled "Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression". This study will evaluate the efficacy and safety of NV-5138 in adults with TRD

What is the current status of trial NCT05066672?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2022-01-18. Estimated completion is 2025-01-21.

What interventions are being tested in trial NCT05066672?

The interventions under investigation include: NV-5138 (DRUG), matched placebo (DRUG).

Who is sponsoring clinical trial NCT05066672?

This trial is sponsored by Navitor Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.